Economic sustainability of healthcare systems and role of HTA. News from Europe! www.fondazionearpa.it Journal Club – HEMA Alumni Kellogg School of Management.

Slides:



Advertisements
Similar presentations
4 th Meeting of the EC International Dialogue on Bioethics Copenhagen, June 19 th, 2012 Large research and medical databases in clinical and research multi-centred.
Advertisements

Policies and Procedures for Civil Society Participation in GEF Programme and Projects presented by GEF NGO Network ECW.
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Universal Coverage – Can we guarantee health for all? 3 – 4 October 2011, Kuala Lumpur Nossal perspective.
How do we achieve cost effective cancer treatments in the UK? Professor Peter Littlejohns Department of Public Health and Primary Care.
No. 1 Organizing Eldercare The Danish Case in a Comparative Perspective Morten Balle Hansen, Professor, PhD Department of Political Science, Aalborg University.
Socio-Economic Implications of Health Disparities International Council on Social Welfare - ICSW Tuvia Horev Taub Center for Social Policy Studies in Israel.
Health Technology Assessment and evidence-informed decision making
NICE and NICE’s equality programme in 2012 Nick Doyle Clinical and public health analyst.
The Right to Health Protection. Art. 1º All human beings are born free and equal in dignity and rights. They are endowed with reason and conscience and.
A tisket, a tasket, is MNCH in your benefits basket? March 2, 2015.
Integration, cooperation and partnerships
HTA & Medical Devices: An International Perspective Christina Farup, MD, MS | April 2015.
PUBLIC & PRIVATE HEALTH CARE IN CANADA before the Canadian Pension & Benefits Institute Winnipeg - June 15, 2007 by Norma Kozhaya, Ph.D. Economist, Montreal.
‘ Social injustice is killing people on a grand scale ’ ‘ A new approach to development ’ economic growth is without question important, particularly for.
The Rehabilitation in the Community of Persons with Mental Disabilities Law of Israel: Challenge and Opportunity in a Changing Mental Health Service System.
LIMITLESS POTENTIAL | LIMITLESS OPPORTUNITIES | LIMITLESS IMPACT Copyright University of Reading IMPACT AND THE SCIENCES Anthony Atkin (Research Impact.
OECD experience on fiscal sustainability Joint OECD/WHO Meeting on Financial Sustainability of Health Systems Edwin Lau Deputy Head, Budgeting & Public.
LOCAL GOVERNANCE IN THE 21 ST CENTURY: FRAUD, CORRUPTION AND ETHICS (THE UGANDA EXPERIENCE) PAPER PRESENTED AT TRAINING WORKSHOP HELD AT DOCKLANDS HOTEL.
Georgian Health Care 2020 Washington DC, February 1-2, 2010
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Current Approaches in European Health Care Policy What models can balance the needs of payors and industry?
HSC Core 1: Health Priorities in Australia
© Nuffield Trust The organisation of hospital services in Europe: Recent trends and strategic choices Dr Rebecca Rosen Senior Fellow The Nuffield Trust.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Creating a New Vision for Kentucky’s Youth Kentucky Youth Policy Assessment How can we Improve Services for Kentucky’s Youth? September 2005.
How to determine medicines benefits policy and program needs?
The Czech Health System – its Presence and Future Pavel Hroboň L.Dittrich.
OECD work on health Y-Ling CHI, Health Policy Analyst, Health Division, Organisation of Economic Cooperation and Development.
Public Financial Management: An Introduction Training for Support PAC Staff Hilton Hotel, Windhoek, Namibia May 2012.
Institutional Development for Improved Water Quality | November 2010 Operation and Maintenance for Safe Drinking Water – Institutional development to achieve.
1 Webinar: Challenges in Clinical Training Ben Wallace, Executive Director, Clinical Training Reform Health Workforce Australia.
Health Care Facts and Guiding Principles for Health Care Reform Public Employees Union, Local #1.
Ms Rebecca Brown Deputy Director General, Department of Health
3 August 2004 Public Health Practice III: FINANCING PUBLIC HEALTH REFORM Thomas E. Novotny MD MPH University of California San Francisco Institute for.
Svetlana Spassova, MD Ministry of Health, Bulgaria Chisinau
Improving Access and Quality Use of Medicines in Palliative Care within National Drug Policy, Regulatory, and Funding Frameworks Debra Rowett, Tania Shelby-James,
Potential Roles for Health Technology Assessment Agencies: Opportunities and Challenges for an Effective Health Technology Assessment Practice at the Meso.
Competitiveness of the European-based Pharmaceutical Industry Prospective of a New Member State Imre Hollo Deputy Secretary of State, MOH Hungary.
European Commission Introduction to the Community Programme for Employment and Social Solidarity PROGRESS
Health challenges in an enlarged Europe Report from Parallel Session A1 Dr. Natasha Azzopardi Muscat Ministry of Health - Malta.
DETERMINE Working document # 4 'Economic arguments for addressing social determinants of health inequalities' December 2009 Owen Metcalfe & Teresa Lavin.
Ministry of Healthcare & Nutrition Broader Approaches to Health Strategic Frame Work for Health Development.
Themes Emerging from Country and Related Presentations Notes from session 1545 – 1730 Thursday 17 February 2011 Albert Weale.
HTA Benefits and Risks Dr Bernard Merkel European Commission.
Policies and Procedures for Civil Society Participation in GEF Programme and Projects presented by GEF NGO Network ECW.
© Safeguarding public health Can Europe grow its Medtech industry and lead the world on medical device regulation? John Wilkinson 20 th September 2012.
HEALTH FINANCING MOH - HPG JAHR UPDATE ON POLICIES Eleventh Party Congress -Increase state investment while simultaneously mobilizing social mobilization.
Regulation Inside Government: Approach and lessons learned Punita Goodfellow, Better Regulation Executive, Cabinet Office, UK.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
1 Brussels 16 January What is HOPE? HOPE is an excellent example of the diversity of European healthcare system What is HOPE? HOPE is an excellent.
World Health Organization Department of Chronic Diseases and Health Promotion World Health Organization Strengthening Institutions: Indicators for Measuring.
Modernizing Health Care Inez Bartels.  Strong focus on the provision of health care  Institutions governing health care consumption control patients.
Health Technology Assessment Methodology, an EUnetHTA View Basics for the Assessment in EU Countries PharmDr. Martin Visnansky, MBA, PhD., MSc. (HTA) HTA.
Week 12. Lecture 2. Health Law & the EU Cross-border healthcare: patients’ rights.
Autumn Staff briefings As a NHS patient, care is provided free at the time you need it, whether this is from a hospital or community nurse or.
Liberating the NHS: Developing the healthcare workforce Workforce planning, education and training Consultation Engagement.
The Workforce, Education Commissioning and Education and Learning Strategy Enabling world class healthcare services within the North West.
Reforming the State System for the provision of social services, setting the vision, aims and objectives: The United Kingdom Experience Mr Sean Holland.
European network for Health Technology Assessment | JA | EUnetHTA European network for Health Technology Assessment THL Info.
RESOURCES AND CORPORATE DEVELOPMENT SCRUTINY COMMITTEE Tuesday 17 th June 2003 RESOURCES DIRECTORATE Julie Alderson Executive Director Resources.
FUNDAMENTALS OF PUBLIC HEALTH Joseph S Duren Lopez Community & Public Health - HCA415 Instructor: Adriane Niare November 10, 2015.
Health Sector Functional Review Context & Preliminary Results for Policy Options Discussion Health Sector Workshop Belgrade – March 24, 2016 World Bank.
Presentation to the Health Portfolio Committee Presentation to Health Portfolio Committee Free State Department of Health 15 APRIL 2003.
Health Technology Assessment
Patient Involvement in the HTA Decision Making Process
Community Pharmacy: Sharing Our Vision
Health Technology Assessment for Universal Health Coverage
Health Technology Assessment in India
How can we make healthcare purchasing in Kenya more strategic?
Presentation transcript:

Economic sustainability of healthcare systems and role of HTA. News from Europe! Journal Club – HEMA Alumni Kellogg School of Management Northwestern University Giuseppe Turchetti, PhD Scuola Superiore Sant’Anna – PISA (Italy) Fulbright Scholar at Kellogg School of Management Evanston, June

The Italian health care system The economic sustainability of the system The role of Health Technology Assessment Prospective evolution and open issues Key points of the presentation

The Italian health care system The economic sustainability of the system The role of Health Technology Assessment Prospective evolution and open issues Key points of the presentation

The World Health Organisation (WHO) in World Health Report 2000 ranked the Italian health care system second among 191 countries. The Italian Health Care System

World Health Report

The National Health Service (NHS) was established in The NHS combines public financing with a mixture of public and private provision. The system aimed to grant universal access to a uniform level of care throughout the country, financed by general taxation. The NHS was created to achieve the objective in article 32 of the Italian Constitution, which declares that the Italian State has the responsibility of safeguarding the health of each citizen as an individual asset and a community interest. Moreover, article 32 affirms that the Italian State guarantees free care to the indigent. The National Health Service

Source: Ministry of Health of Italy. Human dignity : Every individual must be treated with equal dignity and have equal rights irrespective of personal characteristics and role in society. Health need : Everyone in need has a right to health care, and resources should be allocated with priority given to satisfying the basic needs of the population. Equity : Any individual must have access to the health care system with no differentiation or discrimination among citizens and no barrier at the point of use. Solidarity : Available resources have to be primarily allocated to support groups of people, individuals and certain diseases that are socially, clinically and epidemiologically important. Protection : The individual health has to be protected with appropriate preventive measures and interventions. Effectiveness and appropriateness: Resources must be addressed towards services whose effectiveness is grounded and individuals that might especially benefit from them. Priority should be given to interventions that offer greater efficacy in relation to costs. The individual health has to be protected with appropriate preventive measures and interventions. The National Health Service: Principles

Parliament Government Ministry of Health departments National Health Fund – National Solidarity Fund National budget National Institutes for Scientific Research (IRCCS) A Agency for Regional Health Care Services Central level Regional level Regional health departments Regional health fund Regional agencies for health Regional governments Regional budgets Local level Local health authorities Health districts Hospitals Health Promotion divisions Public hospital trusts Private accredited hospitals Citizens Patients Services Co-payment Other programmes A National bodies (technical support to the Ministry of Health) National Institute of Health National Health Council National Institute of Occupational Safety and Prevention Administration and planning Policy and legislation Main financial flow (citizens-NHS/ regional health services)

The central level  National bodies (technical support to the Ministry of Health)  National Institute of Health  National Health Council  National Institute of Occupational Safety and Prevention Parliament Government Ministry of Health departments National budget National Institutes for Scientific Research (IRCCS) Agency for Regional Health Care Services Citizens Patients Other programmes Administration and planning Policy and legislation Main financial flow (citizens-NHS/ regional health services) The Ministry of Health is the main central institution. It manages the National Health Fund and it ensures five different functions, through its department and services: 1.health care planning; 2.health care financing; 3.framework regulation; 4.monitoring; 5.general governance of the National Institutes for Scientific Research (IRCCS). National Health Fund – National Solidarity Fund

The regional level Administration and planning Policy and legislation Main financial flow (citizens-NHS/ regional health services) Regional health departments Regional health fund Regional agencies for health Regional governments Regional budgets Citizens Patients They are responsible for legislative and administrative functions, for planning health care activities, for organizing supply in relation to population needs and for monitoring the quality, appropriateness and efficiency of the services provided. The regional level has: 1.legislative functions; 2.executive functions; 3.technical support and evaluation functions. Regional governments are responsible for pursuing the leading national objectives posed by the National Health Plan at the regional level. Regional health departments are required to guarantee the benefit package to be delivered to the population through a network of population-based health care organizations (local health units) and public and private accredited hospitals.

The local level Local health authorities Health districts Hospitals Health Promotion divisions Public hospital trusts Private accredited hospitals Starting in 1992, a network of public and private health care structures and providers was operating at the local level that can be divided into four different categories:  Local health authorities;  Public hospital trusts;  National Institutes for Scientific Research (IRCCS);  Private accredited providers.

The Italian health care system The economic sustainability of the system The role of Health Technology Assessment Prospective evolution and open issues Key points of the presentation

Source: OECD Health Data 2011; WHO Global Health Expenditure Database OECD countries allocate 9.6% of their GDP to health, ranging from over 17% in the United States to just over 6% in Mexico and Turkey. Indonesia, India and China spend less than 5% of GDP on health

Source: OECD Health Data 2011; WHO Global Health Expenditure Database The share of GDP allocated to health is increasing in all OECD countries, as health spending is growing much faster than GDP

Source: OECD Health Data 2011; WHO Global Health Expenditure Database Annual average growth rate in health expenditure per capita in real terms, (or nearest year) Across OECD countries, health expenditure has grown by 4% annually over the past decade, compared with 1.6% for GDP growth

Which is the return on the investment? Relationship between expense and health indicators Relationship between presence/expense in health technology and health indicators

Life expectancy at in OECD countries Source: OECD Health Data 2011; WHO Global Health Expenditure Database

Health care expenditure has risen considerably over time … Health technology is the first cause!  Technology innovation in medicine is the first cause of the quadruplication of the healthcare expenditure over the period  Less than half of the expenditure can be explained by: increase in moral hazard, higher administrative expenses, and other modifications of the supply and demand mechanism. The other part is caused by health technology innovation.  In USA about two-third (70%) of the medical spending growth and about three-fourth (76%) in the medical spending growth came from cost-increasing advances in medical technology.

Also the level of Health has increased … Life expectancy at birth has increased by 11 years in OECD countries since 1960, reflecting declines in mortality at all ages Source: OECD Health Data 2011; WHO Global Health Expenditure Database Which part of this health improvement is caused by health services and by health technology innovation?

Are technological innovations in medical devices and in medicine financially sustainable? How much health care can we afford? It is new technology that we would look to for cost savings? The sustainability of the system: is it too expensive?

The Italian health care system The economic sustainability of the system The role of Health Technology Assessment Prospective evolution and open issues Key points of the presentation

Health Technology Assessment (HTA) The Health Technology Assessment is a multidisciplinary research area aimed at make “informed” health policy decisions (at the institutional level, individual health organizations and clinical practice) through the assessments of the clinical, economical, ethical, legal and organizational implications regarding the adoption of health technologies. “We shall use the term assessment of a medical technology to denote any process of examining and reporting properties of a medical technology used in health care, such as safety, efficacy, feasibility, and indications for use, cost, and cost effectiveness, as well as social, economic, and ethical consequences, whether intended or unintended.” (Institute of Medicine 1985)

The goal of HTA is to inform the development of safe and effective health policies that are patient focused and seek to achieve best value as defined by decision makers. HTA underpins decisions such as: Should treatment A be reimbursed in a national healthcare system? For which patients should it be provided? For how long should patients receive the treatment? Although the scientific assessment of the available data may be similar wherever the HTA is undertaken, the way in which a technology is appraised (that is, how the assessment is used to devise recommendations on its value in healthcare) may vary from country to country. As a result, different decisions are taken about which technologies should be provided, leading to variation in access to treatments. Health Technology Assessment (HTA)

Technical properties/Specifications : performance, reliability, ease of use and maintenance of technology; Safety : acceptability of risk associated with the use of technology; Efficacy and effectiveness : contribution made by technology to improving the health status of the patient. Efficacy refers to benefits arising from the use of technology in "ideal“ conditions (for example under a clinical trial protocol). Effectiveness considers the benefit derived from the use of a technology under normal conditions; Economic impact : assessment of costs, prices, levels of payment associated with a single technology. The impact is also considered by a macroeconomic point of view (analysis of financing systems and services reimbursement, policies for technological innovation and competitiveness …); Social, legal, ethical and/or political impact: methods applicable for the technologies evaluation are inadequate or nonexistent, but for some technologies can not be irrespective of their consideration. Health Technology Assessment: the evaluation of health technologies

SBU (Swedish Council on Technology Assessment in HC) CCOHTA (Canadian Coodrdinationg Office for Health Technology Assessment) – 1989 (from 2006: Canadian Agency for Drugs and Technology in Health) PBAC (Pharmaceutical Benefits Advisory Committee - Australia) – 1992 IQWiG (Institute for Quality and Efficiency in HC – Germany) NICE (National Institute for Health and Clinical Excellence) EVALUATING VALUE FOR MONEY Relevant HTA experiences

HTA experiences in Europe

HTA experiences in Europe

HTA experiences in Europe

HTA experiences in Europe

HTA experiences in Europe

The Italian health care system The economic sustainability of the system The role of Health Technology Assessment Prospective evolution and open issues Key points of the presentation

Control on HC Technologies Prospective evolution? Reduction of the HC Technology expenses Reduction of HC expense Which implications in term of: Waiting lists Quality of care Diagnostic and therapeutic opportunities Rationing of procedures! Equity of access Future innovation

4 A wider evaluation is necessary!  Organizational impact  Extra hospital costs  Recovery time  Impact on pain and quality of life  Impact on MDs training courses and other involved professionals  Impact on future innovation: technological, organizational and surgical technique  Impact on other disciplines Prospective evolution

How to make the system sustainable? How to increase the health indicators at a national/international level? How to increase the ROI of the investment in HC technology? More technology? Better technology? Better use of technology? Open issues

6 Personal thoughts In which direction should we move?  Creating culture in all stakeholders  Innovation  Sustainability  Appropriateness  Efficiency  Value How? Producing evidences! - Cost-effectiveness studies - Analysis of the cost of the different procedures - HTA studies

Is this our scenario in the near future? Health care costs He has no chances!

We must give answers!

But not this kind of answers...!

….Technology could always help us…. X-RAYS SHOWED A BROKEN RIB, BUT WE ARRANGED WITH PHOTOSHOP

Economic sustainability of healthcare systems and role of HTA. News from Europe! Journal Club – HEMA Alumni Kellogg School of Management Northwestern University Giuseppe Turchetti, PhD Scuola Superiore Sant’Anna – PISA (Italy) Fulbright Scholar at Kellogg School of Management Evanston, June